Aquestive Therapeutics, Inc.

AQST

US03843E1047

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 23/05/2024 am IST			5-day change	1st Jan Change
3.15 ^USD	-0.94%		-2.17%	+55.94%

10/05	Leerink Partners Starts Aquestive Therapeutics With Outperform Rating, $8 Price Target	MT
08/05	Transcript : Aquestive Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024

Aquestive Therapeutics, Inc. Reaffirms Earnings Guidance for the Year 2021

May 05, 2021 at 12:53 am IST

Aquestive Therapeutics, Inc. reaffirmed earnings guidance for the year 2021. For the year, the company expects total revenues of approximately $38 million to $42 million.

Latest news about Aquestive Therapeutics, Inc.

Leerink Partners Starts Aquestive Therapeutics With Outperform Rating, $8 Price Target	10/05	MT
Transcript : Aquestive Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024	08/05
Earnings Flash (AQST) AQUESTIVE THERAPEUTICS Posts Q1 Revenue $12.1M, vs. Street Est of $12.3M	08/05	MT
Aquestive Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
Aquestive Therapeutics, Inc. Provides Earnings Guidance for the Full Year 2024	08/05	CI
Aquestive Therapeutics Obtains FDA Approval for Libervant to Treat Seizure in Children	29/04	MT
Transcript : Aquestive Therapeutics, Inc. - Special Call	29/04
Aquestive Therapeutics, Inc Receives U.S. FDA Approval and Market Access for Libervant? Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm? (epinephrine) Sublingual Film	29/04	CI
Aquestive Therapeutics, Inc. to Present Crossover Study Data for Libervant Buccal Film At 76th Annual Meeting of the American Academy of Neurology	13/04	CI
Piper Sandler Initiates Aquestive Therapeutics at Overweight With $10 Price Target	11/04	MT
Aquestive Therapeutics Files $250 Million Mixed Shelf	04/04	MT
Aquestive Therapeutics, Inc. Appoints Abigail Jenkins to Board of Directors, Effective April 1, 2024	01/04	CI
Raymond James Initiates Aquestive Therapeutics With Outperform Rating, $7 Price Target	28/03	MT
Top Midday Decliners	20/03	MT
Sector Update: Health Care Stocks Steady Premarket Wednesday	20/03	MT
Wall Street Set to Open Flat as Investors Look Toward Fed Decision; Oil Prices Drop Sharply	20/03	MT
Top Premarket Decliners	20/03	MT
Aquestive Therapeutics Prices $75 Million Common Stock Offering; Shares Slump Premarket	20/03	MT
Aquestive Therapeutics Prices $75 Million Common Stock Offering	20/03	MT
Aquestive Therapeutics Proposes Public Stock Offering -- Shares Drop	20/03	MT
H.C. Wainwright Raises Price Target on Aquestive Therapeutics to $9 From $7, Maintains Buy Rating	18/03	MT
JMP Securities Adjusts Price Target on Aquestive Therapeutics to $10 From $8, Maintains Market Outperform Rating	15/03	MT
Sector Update: Health Care Stocks Edge Higher Premarket Friday	15/03	MT
Aquestive Therapeutics' Anaphylm Demonstrates Faster Maximum Concentration Reach in Phase 3 Trial	15/03	MT
Aquestive Therapeutics, Inc. Releases Positive Topline Clinical Data from Its Phase 3 Pivotal Pharmacokinetic (PK) Clinical Study of Anaphylm (Epinephrine) Sublingual Film and Findings from the FDA Type C meeting	15/03	CI

Chart Aquestive Therapeutics, Inc.

Duration

Period

More charts

Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. It is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. It has also developed a product pipeline focused on treating diseases of the central nervous system (CNS). Its PharmFilm technology is comprised of proprietary polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs), and excipients in place. Its product portfolio and pipeline include Anaphylm, AQST-108, and Adrenaverse. Its CNS product candidate include Libervant. The Companyâs Licensed commercial products and product candidates and other product includes Suboxone, Exservan, KYNMOBI, Zuplenz, Azstarys, Libervant, and Sympazan. Anaphylm is a non-device based, orally delivered epinephrine product candidate.

Sector

Pharmaceuticals

Calendar

20/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Aquestive Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.15 USD

Average target price

8.611 USD

Spread / Average Target

+173.37%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
AQUESTIVE THERAPEUTICS, INC.	+55.94%	287M
ELI LILLY AND COMPANY	+37.74%	723B
NOVO NORDISK A/S	+34.67%	595B
JOHNSON & JOHNSON	-2.07%	369B
MERCK & CO., INC.	+20.25%	332B
ABBVIE INC.	+2.99%	282B
ASTRAZENECA PLC	+17.21%	244B
NOVARTIS AG	+9.97%	208B
ROCHE HOLDING AG	-4.13%	205B
AMGEN INC.	+7.43%	166B

Other Pharmaceuticals